Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2.
Karen J Juárez-NavarroEduardo Padilla-CamberosNéstor Fabián DíazAriel Miranda-AltamiranoNéstor Emmanuel Díaz-MartínezPublished in: Stem cells international (2020)
Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals.
Keyphrases
- mesenchymal stem cells
- clinical trial
- sars cov
- umbilical cord
- bone marrow
- risk factors
- endothelial cells
- coronavirus disease
- induced apoptosis
- multiple sclerosis
- hiv infected
- oxidative stress
- cell therapy
- hepatitis c virus
- antiretroviral therapy
- human immunodeficiency virus
- respiratory syndrome coronavirus
- signaling pathway
- cell cycle arrest
- study protocol
- south africa
- drug induced
- endoplasmic reticulum stress
- pluripotent stem cells